| Similar Articles |
|---|
 |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.   |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
June 7, 2007
Brian Lawler |
Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline. |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
June 29, 2005
Karl Thiel |
Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
December 2, 2011
Anders Bylund |
Idenix Pharmaceuticals Shares Surged: What You Need to Know Shares of biotech firm Idenix Pharmaceuticals jumped as much as 11.9% on higher-than-average trading volume. |
The Motley Fool
November 16, 2004
Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
The Motley Fool
March 29, 2006
Stephen D. Simpson |
Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
July 21, 2011
Brian Orelli |
Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda. |
The Motley Fool
February 16, 2007
Brian Lawler |
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
Pharmaceutical Executive
October 1, 2005 |
Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
May 2, 2011
Tim Beyers |
Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
December 19, 2011
Brian Orelli |
ARIAD's Prolific 2011 The biotech is doing something right. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
February 28, 2011
David Williamson |
Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio |
Chemistry World
February 2008
Nuala Moran |
The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
June 18, 2007
Billy Fisher |
Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
